Related Experiment Video

Updated: Jan 3, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.2K

Recent Progress in Characterizing Long Noncoding RNAs in Cancer Drug Resistance

Wenyuan Zhao1, Bin Shan2, Dan He3

  • 1Department of Oncology, Xiangya Hospital, Central South University, Changsha, PR China.

Journal of Cancer
|November 29, 2019
PubMed

Insights

Long noncoding RNAs (lncRNAs) are key regulators of cancer drug resistance, offering novel therapeutic targets. Understanding their diverse mechanisms is crucial for overcoming treatment failure in chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Drug resistance significantly limits the efficacy of cancer chemotherapies.
  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in mediating cancer drug resistance.

Purpose of the Study:

  • To review current research on the mechanisms and functions of lncRNAs in cancer drug resistance.
  • To explore the therapeutic potential and future directions of targeting lncRNAs in cancer treatment.

Main Methods:

  • Literature review of recent studies on lncRNAs and cancer drug resistance.
  • Analysis of identified mechanisms by which lncRNAs influence drug resistance.
  • Synthesis of information on the diverse roles of lncRNAs in promoting or inhibiting drug resistance.

Main Results:

  • lncRNAs regulate cancer drug resistance through various indirect mechanisms, often by modulating intermediate factors.
  • Most lncRNAs promote drug resistance upon overexpression, but some exhibit inhibitory effects.
  • lncRNAs display diverse functions, highlighting their complex involvement in treatment failure.

Conclusions:

  • lncRNAs represent promising targets for overcoming cancer drug resistance.
  • Further research into lncRNA functions can lead to innovative therapeutic strategies.
  • Targeting lncRNAs may offer a new avenue to improve chemotherapy outcomes.
Keywords:
cancerchemotherapydrug resistanceexosomelncRNA

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.0K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K